Genentech's Prasinezumab Phase IIb Study Misses Primary Endpoint But Shows Potential In Early Parkinson's Disease
Genentech's Prasinezumab Phase IIb Study Misses Primary Endpoint But Shows Potential In Early Parkinson's Disease
基因科技的Prasinezumab第二阶段IIb研究未能达到主要终点，但在早期帕金森病中显示出潜力。
*– PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints –
*– PADOVA研究显示运动进展的数值延迟，多个次要和探索性终点呈积极趋势 –
– Prasinezumab continues to be well tolerated and no new safety signals were observed –
– Prasinezumab继续被很好地耐受，没有观察到新的安全信号 –
– Genentech is further evaluating the data and will work together with health authorities to determine next steps –
– Genentech正在进一步评估数据，并将与卫生当局合作判断下一步措施 –
资讯热榜
更新时间